Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Add insider buying to my list.
BIPH - Investment Thesis
Huge market potential.
Maxed out SS - AS 250 MM - OS 243MM
Loyal stockholder base.
Cash on hand to fund ops through 2009.
No long term debt.
Eliminated convertible toxic debt.
Milestone patent just awarded after 6 year prosecution at USPTO.
Deep and expanding patent portfolio.
Possible acquisition target.
Recurring revenues.
Market cap at 1% of historical highs.
Insiders buying stock.
http://www.secform4.com/insider-trading/1084000.htm
Hello Dart, Would you mind posting a NEOM chart and any commentary you would add. TIA
The maxed out share structure could very easily work to the benefit of shareholders here. With no concerns of dilution for at least two months and the float locked up by a group of strong loyal longs, this thing would move north rapidly with any sustained buying pressure. This stock is flying under everyones radar as only the longs here realize the potential. I intend to do what I can to get the word out and I-hub is a great format to accomplish that objective.
BIPH - Investment Thesis
Huge market potential.
Maxed out SS - AS 250 MM - OS 243MM
Loyal stockholder base.
Cash on hand to fund ops through 2009.
No long term debt.
Eliminated convertible toxic debt.
Milestone patent just awarded after 6 year prosecution at USPTO.
Deep and expanding patent portfolio.
Possible acquisition target.
Recurring revenues.
Market cap at 1% of historical highs.
Just a short list of some of the reasons I am here.
Time to get proactive!!
This proxy is starting to make less and less sense to me. With every day that passes and with every pre- date of record - share that is traded the likelihood of passage seems more remote.
What do you want the shares for management? Might help if you would let your voters know the plan!!
Sheesh!!!
FWIW
In 2005 BIPH issued 64 PR's
In 2006 BIPH issued 44 PR's
In 2007 BIPH issued 21 PR's
In 2008 BIPH issued 16 PR's
Since 9/08 BIPH has issued ZERO PR's
I made my first purchase of stock off the last PR (eliminates dilutive financing) What's the big secret now? I think it's time that the company issued some sort of communication with it's shareholders other than SEC filings.
Picking up a few more of these cheapies though while I wait....
BIPH - on sale - Don't miss out - Sale ends ??????????
Got me, I don't make the news, I just copied and pasted what I found.
IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS
TEXARKANA DIVISION
Judge David Folsom
SCANBUY )(
)(
V. )( CIVIL NO. 5:08CV199
)(
NEOMEDIA TECHNOLOGIES )(
________________________________________________________________________
ATTORNEY FOR PLAINTIFFS: John Mercy; John Hintz
ATTORNEY FOR GOVERNMENT: Trey Schroeder; Jeff Pine
LAW CLERK: Michael Bittner
COURTROOM DEPUTY: Mel Martin
COURT REPORTER: Libby Crawford
_________________________________________________________________________
SCHEDULING CONFERENCE
February 25, 2009 @ 10:30 am
OPEN: 10:29 ADJOURN: 10:38
_________________________________________________________________________
10:29 ct/ technology;
10:29 Hintz/ simple technology;
10:30 Pine/ responds;
10:30 ct/ if agreement is not reached, write letter to ct letting us know that the motion is ripe;
discovery
10:31 Hintz/ responds;
10:32 ct/ sounds like you are working together well; had a 11/12th claim construction date open up;
does that sound reasonable;
10:33 ptys agree;
10:33 ct/ normal practice Mkmn on Thursday and tutorial day before but, day before is a holiday;
tutorial no more than 30 mins each side;
10:33 Hintz/ would you like that live or on DVD
10:33 ct/ no preference; time for claim construction; normal practice is 90 mins each side and can
combine tutorial with that, then I could give an additional 30 mins;
10:34 Hintz/ 2 hrs would be the outer limit;
10:34 ct/ 2 hrs each side and if you feel tutorial is not needed then we will reduce it to 90 mins each
side; pending New York case;
10:35 Hintz/ responds;
10:36 ct/ discovery;
10:36 Hintz/ don’t think we had any disputes;
10:36 ct/ normal limitation;
10:36 Pine/ 7 hrs on subject matter;
10:36 ct/ what do you mean;
10:36 Pine/ responds;
10:37 ct/ seem to be working well so I will allow that; protective order;
10:37 Pine/ making some revisions;
10:37 ct/ have protective order by 3/27th or competing orders if unable to agree; Mkmn preference,
term, response and then reply; normal limitation of 10 claims for claim construction; any other
matters;
10:38 recess;
IMO the risk just shifted from being "in" to being "out".
Would not want to be sitting on the sidelines if news of that nature were to hit the wires.
Things that make you go hmmmmmm!
Nice catch!
Done deal! Big milestone for BIPH IMO
"I mean they may be Antipodean rabbits and therefore considered by some to be dispensable, but isn't about time Biophan went back into humans, but this time under proper clinical trial conditions so that the FDA approval process can begin?"
Answer: Yes!! stay tuned
Here's the link, Its in the I-box under must see videos.
http://www.biophan.com/index.php?option=com_content&task=view&id=495&Itemid=471
Very interesting!!
MONDAY JANUARY 26, 2009
90 The Society of Thoracic Surgeons 45th Annual Meeting 91
New | Special Interest
Ticketed Event1:45 pm
17. Non-Blood Contacting Support Device Effectively Augments Myocardial Function of the Neonatal-Sized Failing Heart
S. Budharaju1, A. J. Pothoulakis1, L. J. Prochaska1, S. A. Kerns1, R. J. Darner1, B. A. Schmitt1, P. M. Portner2, M. P. Anstadt1
1Wright State University School of Medicine, Dayton, OH; 2Stanford University School of Medicine, Stanford, CA
FINANCIAL DISCLOSURE P.M. Portner, consultant to company and board member, Myotech, LLC; M.P. Anstadt, consultant and board member, Myotech, LLC, ownership of shares, Myotech, LLC
REGULATORY DISCLOSURE This presentation describes the use of Sapien Edwards whose FDA status is investigational, Cove Valve whose FDA status is investigational, and Ventor whose FDA Status is investigational.
Background: Direct Mechanical Ventricular Actuation (DMVA) is a non-blood contacting method that uniquely augments both systolic and diastolic ventricular function. DMVA technology (the MyoVAD) is currently under development for the small pediatric or neonatal heart. The purpose of this study was to assess DMVA feasibility for biventricular support of the neonatal-sized failing heart.
Methods: New Zealand white rabbits (n=6) were anesthetized, underwent sternotomy and instrumented for hemodynamic monitoring. A 10mHz ultrasound probe was positioned for transesophageal cardiac imaging. Heart failure (HF, cardiac output < 50% baseline) was induced with esmolol while phenylephrine was titrated for maintaining mean arterial pressure (60-70mm Hg). Steady state ECHO images were acquired during baseline, HF and subsequently DMVA during 2 hours of support. Images were analyzed for ejection fraction, stroke volume and cardiac output using Simpson’s method of discs as measures of LV function. Velocity Vector Imaging (VVI) was used to assess peak systolic and diastolic strain rates in the basal, mid, and apical regions of the LV septum and LV free wall. Peak global systolic and diastolic strain rates were used as load independent measures of myocardial systolic and diastolic function
Conclusions: In this study, DMVA provided effective non-blood contacting biventricular support of the neonatal-sized heart. Importantly, both systolic and diastolic myocardial function were significantly augmented which represents a distinct advantage to the limited systolic assist offered by direct cardiac compression devices. These findings demonstrate feasibility for supporting the pediatric and neonatal-sized failing heart using the MyoVAD technology. Future studies will assess support of congenital conditions such as the univentricular heart.
The Society of Thoracic Surgeons Page 90
http://www.sts.org/documents/pdf/annmtg/2009AM/45thprogram_monday.pdf
It's nice to see a little optimism in NEOM land even though it continues to be clouded by pessimism. I guess any form of exuberance is better than the totally negative bias (myself included) that has been prevalent for so long. Here's hoping for a green week!
Ensuring the safety of medicines in the EU:
GS1 Standards in Healthcare
Global and open standards permit full interoperability and compatibility. End users are
not locked into proprietary solutions. It also strengthens the competitiveness of
European companies by aligning national solutions and thus removing barriers impeding
access to other markets.
Country-specific regulations may satisfy the needs of those countries, but when products
move across borders throughout the global supply chain, this causes problems:
- difficult to achieve implementation on a national level due to the complexity of the
myriad of systems required for various local requirements
- identification numbering schemes developed for one tracking system won’t
necessarily be recognised by another
- the cost burden to the stakeholders in the Healthcare supply chain will increase
significantly
http://ec.europa.eu/enterprise/pharmaceuticals/pharmacommunication/contributions/industry/gs1_european_commission_consultation_pharmaceuticals_gs1_hug.pdf
EFPIA is making plans to launch a pilot scheme of a unique bar code system, which will
enable the pharmacist to verify each medicine pack before dispensing it to the patient. This
pilot will be launched before the end of 2008. The technology used – the 2 dimensional
data matrix – is considered the best option today and could be used as an EU standard
http://www.sefh.es/sefhpublicaciones/boletinesEAHP/Junio2008.pdf
4. Format
For discussion purposes, ISMP Canada proposes that the data format standards
developed by either GS1 or HIBCC be deemed acceptable.
5. Symbology
For discussion purposes, ISMP Canada proposes that the guidelines recommend
two-dimensional (Data Matrix) symbology.
http://www.ismp-canada.org/download/PharmaceuticalBarCodingtoImprovePatientSafety-ISMPCanadaJan08.pdf
Thanks claw, there is no question that NEOM knew on Feb 4th that they would get the patent win.
Not to my knowledge, there was one scheduled for Feb 10 I believe, but the judge died apparently. There is a hearing in the Texas case on Feb 25th.
Why has there been no response to this order? Claw,Beam how much time would be considered appropriate to respond? Why would NEOM not respond that they were ready to move forward directly after learning of the USPTO decision on Feb 4? Are the parties attempting to settle as we speak?
Let the enforcement begin!!
Jonsie, somehow "narrow" just doesn't seem to fit.
That's just funny, I love this line in particular.
"if you're trying to decide what course of action to take in light of the reissued patent, you may want to hire a patent attorney to discuss with you the specifics of your plan".
Suggested edit - suggest you hire a damned good patent attorney in other words, avoid those of us at the EFF!!
Thanks for posting rwandrw
Thanks Streets, that document is lengthy but contains a lot of good information. Everyone should at least take the time to look at the first few pages and look at the organizations that are involved or contributing which does btw include Thomas Hinterleithner - Gavitec AG - Content Contributor
The potential is truly enormous!!
Here's an excerpt -
A brand owner calls back specific lots of products with defects. The call is relayed through the media, not always specifying which lots are defective. At home (or anywhere with the product), the consumer can scan the barcode on the packaging to see if the product is concerned, or receive a direct message for a product that can be confirmed by scanning.
Got any peanut butter your not sure about??
GS1 MobileCom
Extended Packaging Pilot Handbook
Issue 1, 11-Feb-2009
http://www.gs1.org/docs/mobile/GS1_Extended_Packaging_Pilot_Handbook.pdf
"The indirect mode is the only way of access to Extended Packaging information when using linear barcodes. Both the direct and indirect mode of access is possible with 2D GS1 barcodes."
Do not see Neom mentioned anywhere in the document. Rather strange considering they hold the patent that enables the tech.
Streets or anyone can you help me out here, what is NEOM's relationship with GS1? TIA
I know what I know, and with every post I learn more about what you don't. They have converted zero shares under the conversion terms that you reference. Back to school!
Actually, its 90% of the last 30 but your close. Your kinda like a student arguing with the teacher it seems to me.
NEOM has known of the patent win since Feb 4th according to the dates available on USPTO site.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35689968
I wonder why we have not heard news of the completion of the $4mm final round of funding. Could it be that NEOM does not need it because of the following statement by IM in the latest PR? Are licensing deals already providing revenue? I'm putting my money on YES!
"NeoMedia is licensing its technology to foster innovation in the creation of exciting new mobile barcode applications and services for the advertising industry."
http://neom.com/press-021809.php
Board Marks still climbing, kinda nice to have some new folks helping with the heavy lifting. Welcome all, and keep doing your DD, your going to find massive potential but also a significant risk/reward profile. The longs here are some of the finest DD folks anywhere and a great source of knowledge.
GLTA
There are certainly several organizations that could be considered to be infringing, but it is my hope that this decision leads to multiple licensing agreements including royalties. Quickest path to substantial revenue and a turn for NEOM's financial status.
Of course if they don't see the light they should be prepared to deal with the eventual consequences.
The patent that was just upheld is all about "indirect" linking to content from barcodes etc.
Don't generally post on this board so this post probably got overlooked, but I did try to sound the alarm on the news this AM.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35682826&txt2find=neom
This might help clarify the situation for you.
Because a reexamination certificate is being issued. The reexam process is way to complicated to explain in brevity. This news has been long awaited by those that hold NEOM stock and is excellent news!!
You have that all wrong -- keep looking! The patent was first issued in 1995 and a third party challenged the patent with the USPTO. The news relates to the patent office decision to uphold the patent as originally issued. Potential billions to be made from the technology.
Next up -- resolution to this long standing dispute? I'm thinking that SB will be looking for a way out of their situation very soon!!
U.S. District Court [LIVE]
Eastern District of TEXAS (Texarkana)
CIVIL DOCKET FOR CASE #: 5:08-cv-00199-DF
Scanbuy, Inc. et al v. Neomedia Technologies, Inc.
Nature of Suit: 830 Patent
Jurisdiction: Federal Question
02/09/2009 NOTICE of Hearing: Scheduling Conference reset for 2/25/2009 10:30 AM in Ctrm 319 (Texarkana) before Judge David Folsom. (mrm, ) (Entered: 02/09/2009)
(12) The possibility of early mediation
Plaintiffs believe that early mediation would be productive based on the long-standing
dispute between the parties pending in the United States District Court for the Southern District
of New York and the parties past, productive efforts at reaching an agreed settlement of that
action. Plaintiffs expect that any such mediation would encompass both that action and this
action. Defendant does not necessarily disagree, but the track record on attempts at settlement in
the past is not good.
IMO we will be taking the "indirect" route to a similar or better market cap.
NEOM HOD .0046 up 170% Lot's of room to run - multiple bagger potential from here!
NEOM HOD .0046 up 170% Lot's of room to run - multiple bagger potential from here!
Pretty, isn't it !!!
Patent detail is now available on USPTO site.
http://portal.uspto.gov/external/portal/pair
Just gettin started here IMO! Last time we thought we had a favorable decision she ran to .035, albiet we had a few less shares in the float. This time though we have a hotter market to operate in. IMO YA will let her run. GLTA